Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Overcoming Resistance to Immunotherapy Combining Gemcitabine With Atezolizumab in Advanced NSCLC and Mesothelioma Progressing Under Immune-checkpoint Inhibitors or Gemcitabine. A Multicenter, Single-arm, Open Label Phase II Trial With Two Cohorts

NCT04480372 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT04480372
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04480372 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Overcoming Resistance to Immunotherapy Combining Gemcitabine With Atezolizumab in Advanced NSCLC and Mesothelioma Progressing Under Immune-checkpoint Inhibitors or Gemcitabine. A Multicenter, Single-arm, Open Label Phase II Trial With Two Cohorts
Lead sponsor
Swiss Cancer Institute
Phase
Phase 2
Overall status
Completed
Start date
March 17, 2021
Completion date
April 3, 2024
Enrollment
68 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

malignant pleural mesothelioma, non-small cell lung cancer